Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020.
- Resource Type
- Academic Journal
- Authors
- Bhatnagar A; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; Boyd S; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; Sabour S; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; Bodnar J; Wadsworth Center, New York State Department of Health, Albany, New York, USA.; Nazarian E; Wadsworth Center, New York State Department of Health, Albany, New York, USA.; Peinovich N; Wadsworth Center, New York State Department of Health, Albany, New York, USA.; Wagner C; Wadsworth Center, New York State Department of Health, Albany, New York, USA.; Craft B; Minnesota Department of Health, St. Paul, Minnesota, USA.; Snippes Vagnone P; Minnesota Department of Health, St. Paul, Minnesota, USA.; Simpson J; Tennessee Department of Health, Nashville, Tennessee, USA.; Stone VN; Tennessee Department of Health, Nashville, Tennessee, USA.; Therrien M; Tennessee Department of Health, Nashville, Tennessee, USA.; Bateman A; Wisconsin State Laboratory of Hygiene, Madison, Wisconsin, USA.; Lower D; Wisconsin State Laboratory of Hygiene, Madison, Wisconsin, USA.; Huang JY; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; Gumbis S; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; Lonsway D; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; Lutgring JD; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; Karlsson M; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; Brown AC; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Source
- Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob Agents Chemother Subsets: MEDLINE
- Subject
- Language
- English
Aztreonam-avibactam is a drug combination pending phase 3 clinical trials and is suggested for treatment of severe infections caused by metallo-beta-lactamase (MBL)-producing Enterobacterales by combining ceftazidime-avibactam and aztreonam. Beginning in 2019, four Antibiotic Resistance Laboratory Network regional laboratories offered aztreonam-avibactam susceptibility testing by broth microdilution. For 64 clinical isolates tested, the MIC 50 and MIC 90 values of aztreonam-avibactam were 0.5/4 μg/ml and 8/4 μg/ml, respectively. Aztreonam-avibactam displayed potent in vitro activity against the MBL-producing Enterobacterales tested.